Last updated: 2026-09-06 22:17:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
IN8bio, Inc. (INAB) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.19, with a market capitalization of $10.84M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.88 to $2.73. This page covers its latest market performance, valuation, price trends and company information.
$10.84M | |
$1.16 | |
$309.57 | |
$0.88 | |
$1.16 | |
22.15K | |
-- | |
-- | |
$2.73 | |
$0.88 | |
-- | |
-- |
IN8bio, Inc. (INAB) last closed at $1.16 as of 2026-09-04 23:21:00, unchanged from the previous close of $1.16.
During the latest regular trading session, INAB traded between $0.88 and $309.57, with a volume of 22.15K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, IN8bio, Inc. (INAB) moved from $1.01 to $1.19, representing a gain of 17.82% ($0.18).
The stock traded between $1.13 and $1.21 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 40.32 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 16.8%
INAB is currently trading at $1.19, placing it 16.8% of the way from its 52-week low of $0.88 to its 52-week high of $2.73. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 18 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of IN8bio, Inc. (INAB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.